The MACD and RSI looks a little overbought. Also the upcoming FDA approval, is not for usage of the drug. But just a Phase 3 fast track evaluation of the drug. Which would take another few months, before an actual approval.
Am expecting a likely correction, which I would buy in a bit more.
On the long term, am bullish of this drug and the tumour imaging agent, it has bought rights for.
Am expecting a likely correction, which I would buy in a bit more.
On the long term, am bullish of this drug and the tumour imaging agent, it has bought rights for.
Comment:
Looks like not much chance of a major correction, with more institutional investors coming in.
Comment:
Seems like a correction till 2.20